27 Aug 2008 07:00
| For Immediate Release | August 27, 2008 |
AorTech AGM Statement
At the Annual General Meeting of AorTech International plc to be held 27 August 2008, Acting Chairman Stuart Rollason, (standing in for Chairman Jon Pither) will make the following statement regarding AorTech's recent Final Results from the period from 1 October 2007 to date:
"The widespread adoption of Elast-Eon™ technology and its success in human clinical applications under numerous customer licences is continuing to progress well. We expect further growth from our polymer licensing and supply business segment.
"We are particularly excited about the potential for our emerging component business. This would be an important additional revenue stream.
The eleventh Annual General Meeting of AorTech International plc will be held in the Mansfield Room of the Marriott Hotel Chancery Court, 252 High Holborn London, WC1V 7EN on 27 August 2008 at 10:00 am.
- Ends -
For further information please contact:
AorTech International plc
Frank Maguire, Chief Executive
Tel: + 1 801 201 4336
Evolution SecuritiesBobbie Hilliam / Chris Clarke
Tel: +44 20 7071 4300
AorTech International plc
Sarah Price, Investor Relations
Tel: + 1 801 550 4349
e-mail sprice@aortech.com
Notes to Editors:
About AorTech International plc
AorTech is the developer and manufacturer of Elast-Eon the world's leading biostable implantable silicone-urethane copolymer. The company is publicly listed in the UK on the Alternative Investment Market exchange (AIM:AOR) with dedicated sales and market development specialists in the US, and its 20,000 square foot ISO-Certified Technology and Biomaterials Manufacturing Center located in Melbourne, Australia.
For additional information go to: www.aortech.com